Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23.

Amélie Boespflug^{1

2

3}, Elisa Funck-Brentano^{4

5}, Zofia Hélias-Rodzewicz⁵, Delphine Maucort-Boulch^{6

7}, Alain Beauchet⁸, Pierre-Paul Bringuier⁹, Charles Dumontet², Jean-François Emile^{5

6

7}, Philippe Saiag^{4

5}, Stéphane Dalle^{1

2

3}

¹ Dermatology Unit, Hospices Civils de Lyon, Pierre-Bénite, France.
² Cancer Research Center of Lyon, Claude Bernard Lyon-1 University, INSERM1052, CNRS 5286, Lyon, France.
³ Pathology Department, Hospices Civiles de Lyon, Pierre-Bénite, France.
⁴ Department of Dermatology, Ambroise Paré Hospital (AP-HP), Boulogne-Billancourt, France.
⁵ Research Unit EA 4340 "Biomarkers in cancerology and in hemato-oncology, University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Boulogne-Billancourt, France.
⁶ Laboratoire de Biométrie et Biologie Evolutive, Biostatistique-Santé team, CNRS UMR 5558, Université Lyon 1, Villeurbanne, France.
⁷ Department of Pathology, Ambroise Paré Hospital (AP-HP), Boulogne-Billancourt, France.
⁸ Department of Public Health, Ambroise Paré Hospital (AP-HP), Boulogne-Billancourt, France.
⁹ Medical Oncology Department, Institut de Cancerologie des Hospices Civils de Lyon, Pierre-Bénite, France.

No abstract available

Publication types